Navigation Links
Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
Date:12/14/2010

NEW BRUNSWICK, N.J., Dec. 14, 2010 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2011 call for nominations. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, significant transformational contributions toward the improvement of human health.  Nominations are available at www.pauljanssenaward.com and will be accepted until February 15, 2011, for consideration by an independent selection committee of world renowned scientists. The winner or winners will receive a $100,000 cash prize.

The Dr. Paul Janssen Award for Biomedical Research honors Dr. Paul Janssen (1926-2003), who is widely recognized as one of the most productive scientists of the 20th century. Known by colleagues throughout the scientific community as "Dr. Paul," Janssen was responsible for breakthrough treatments in disease areas including pain management, psychiatry, infectious disease and gastroenterology and founded Janssen Pharmaceutica, N.V., a Johnson & Johnson Company.

"The Dr. Paul Janssen Award for Biomedical Research recognizes outstanding scientists whose work is game-changing in the development or delivery of critical new treatments and exemplifies Dr. Paul's passion for medical innovation," said Paul Stoffels, M.D., global head, Research & Development, Pharmaceuticals, Johnson & Johnson, who worked for many years alongside Dr. Janssen.

In September 2010, the Award was presented to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) and Erik De Clercq, M.D., Ph.D., chairman of the Department of Microbiology and Immunology of the Medical School at the Catholic University of Leuven. Dr. Fauci received the Award for his ground-breaking contributions to basic and clinical research in the areas of AIDS and other immunodeficiencies. Dr. De Clercq was recognized for his landmark discoveries in anti-HIV medications, including nucleotide analogues, and inventions or co-inventions of six approved drugs for anti-viral therapy.

Previous Award winners include Axel Ullrich, Ph.D., director, Department of Molecular Biology, Max Planck Institute of Biochemistry in Germany; Professor Marc Feldmann, FMedSci, FAA, FRS, and Emeritus Professor Sir Ravinder Maini, FRCP, FMedSci, FRS, of the Kennedy Institute of Rheumatology, Imperial College London; and Craig Mello, Ph.D., Nobel Laureate, of the Howard Hughes Medical Institute and University of Massachusetts Medical School.

"Scientists across the globe work tirelessly to achieve significant and lasting contributions to improving health and well being," said Harlan Weisman, M.D., chief science and technology officer, Medical Devices & Diagnostics, Johnson & Johnson. "In acknowledging and rewarding those contributions, The Dr. Paul Janssen Award inspires us all to embody the scientific passion, compassion and leadership for which Dr. Paul was so well loved and respected."

Beyond the passion and creativity Dr. Paul demonstrated in the laboratory, he also inspired and mentored many young scientific leaders who went on to great achievements in addressing medical need.

"As in past years, we look forward to selecting a 2011 Dr. Paul Janssen Award winner from among the nominations of worthy individuals in research institutions and companies around the world, who has significantly improved human health through dedication to the advancement of science and medicine," said Solomon Snyder, Ph.D., distinguished service professor of neuroscience, pharmacology and psychiatry, Johns Hopkins School of Medicine and 2011 chair of the Dr. Paul Janssen Award Selection Committee.

The 2011 Dr. Paul Janssen Award winner will be announced in the second half of 2011.

About The Dr. Paul Janssen Award for Biomedical ResearchEstablished by Johnson & Johnson, The Dr. Paul Janssen Award salutes the most passionate and creative scientists in basic or clinical research whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. The Dr. Paul Janssen Award is named for Dr. Paul Janssen, who founded Janssen Pharmaceutica, N.V. in 1953. Known to his colleagues as "Dr. Paul," Janssen was one of the 20th century's most gifted and passionate researchers, a physician-scientist who helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization's list of essential medicines. In 1961, Janssen Pharmaceutica, N.V. joined the Johnson & Johnson Family of Companies. Janssen's legacy continues to inspire Johnson & Johnson and its commitment to finding innovative cures for unmet medical needs. Visit www.pauljanssenaward.com for more information.

About Johnson & Johnson Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,400 employees at more than 250 Johnson & Johnson companies work with partners in healthcare to touch the lives of over a billion people every day, throughout the world.Contact:Seema KumarJohnson & Johnson Pharmaceutical Research & Development, L.L.C.908-218-6460 or skumar10@its.jnj.comFrederik WittockJohnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, N.V.+32 14 60 57 24 or fwittock@its.jnj.com
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
2. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
5. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
6. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
7. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
9. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
10. Samplifys AutoFocus™ Beamforming Technology Awarded Electronic Designs Best of 2010
11. Zimmer Awarded Premium Pricing for Trabecular Metal™ Modular Cup in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... ... Plastic Surgery Associates is excited to announce that Heather Furnas, MD, and ... Meeting. Held in San Diego, at the San Diego Convention Center, the annual event ... to the Premier Global Hot Topics session, speaking on genital rejuvenation. , Hosted by ...
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology ... have severe consequences to overall dental health, including complications with speech, eating, and overcompensation ... dental implants to replace lost teeth. As the number of tooth replacements increase, it ...
(Date:4/26/2017)... Aviv, Israel (PRWEB) , ... April 26, 2017 , ... ... today announced a new partnership with Med-e-Mass , the largest Electronic Medical Records ... enable Med-e-Mass to link care plan incentives to a patient’s remote health progress, empowering ...
(Date:4/26/2017)... ... ... Infertility may be a result of an underlying pelvic ... become pregnant upon treating their diagnosis. , To properly diagnose patients, ... can provide the necessary information to diagnose and treat your problem. , ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to ... website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is ... better food, with fewer resources. It highlights the business’ principles, research and collaboration ...
Breaking Medicine News(10 mins):